Repligen Co. (NASDAQ:RGEN) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC boosted its position in shares of Repligen Co. (NASDAQ:RGEN) by 15,586.5% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 40,628 shares of the biotechnology company’s stock after acquiring an additional 40,369 shares during the quarter. International Assets Investment Management LLC owned about 0.07% of Repligen worth $6,046,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. Thrivent Financial for Lutherans lifted its holdings in shares of Repligen by 240.5% in the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock valued at $75,866,000 after buying an additional 425,061 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after buying an additional 237,884 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after buying an additional 121,305 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Repligen by 494.0% in the 1st quarter. BNP Paribas Financial Markets now owns 80,399 shares of the biotechnology company’s stock valued at $14,787,000 after buying an additional 66,864 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the subject of several analyst reports. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. UBS Group cut their price target on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Stephens restated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Finally, JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Price Performance

NASDAQ:RGEN opened at $134.27 on Friday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The stock has a 50 day moving average of $142.48 and a two-hundred day moving average of $146.23. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.52 billion, a P/E ratio of -3,356.75, a price-to-earnings-growth ratio of 3.91 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business’s revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.53 earnings per share. On average, analysts expect that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.